Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis

Background: The combination of immune checkpoint inhibitors (ICIs) and chemotherapy can improve clinical outcomes in the treatment of various tumors, but may also be associated with more adverse events (AEs). We performed a systematic review and meta-analysis to characterize the risk of gastrointest...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wenhan, Men, Peng, Xue, Huimin, Jiang, Mingyan, Luo, Qiuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076172/
https://www.ncbi.nlm.nih.gov/pubmed/32211312
http://dx.doi.org/10.3389/fonc.2020.00197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076172/
https://www.ncbi.nlm.nih.gov/pubmed/32211312
http://dx.doi.org/10.3389/fonc.2020.00197

Ejemplares similares